SCHEMBL21419082

SCHEMBL21419082

CNC(=O)c1nccn1CCNC(=O)OC(C)(C)C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT1 P17948 2/20 0.39
KDR P35968 2/20 0.39
ALDH1A1 P00352 1/20 0.39
GFER P55789 1/20 0.39
DRD2 P14416 3/20 0.38
TDP1 Q9NUW8 1/20 0.38
STK17B O94768 1/20 0.37
STK17A Q9UEE5 1/20 0.37
CA12 O43570 3/20 0.37
CA1 P00915 3/20 0.37
CA2 P00918 3/20 0.37
CA9 Q16790 3/20 0.37
CKS1B P61024 1/20 0.36
SKP1 P63208 1/20 0.36
SKP2 Q13309 1/20 0.36
DYRK1A Q13627 1/20 0.36
MEN1 O00255 1/20 0.36
GAA P10253 1/20 0.36
KMT2A Q03164 1/20 0.36
KDM4E B2RXH2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18839106 0.83 MAPT (0.40) FLT1KDRALDH1A1GFERDRD2
SCHEMBL22588365 0.82 KMT2A (0.44) ALDH1A1GFERDRD2TDP1CA12
SCHEMBL21404331 0.81 RAB9A (0.42) FLT1KDRKMT2A
SCHEMBL21419086 0.81 DRD2 (0.46) ALDH1A1GFERDRD2TDP1STK17B
SCHEMBL31522987 0.81 ALDH1A1 (0.41) ALDH1A1GFERDRD2TDP1STK17B
SCHEMBL3657040 0.81 TLR8 (0.43) ALDH1A1GFERDRD2TDP1STK17B
SCHEMBL28230449 0.80 ALDH1A1 (0.43) ALDH1A1GFERDRD2TDP1STK17B
SCHEMBL1568448 0.79 HTT (0.43) ALDH1A1GFERDRD2TDP1STK17B
SCHEMBL29951923 0.79 ALDH1A1 (0.40) ALDH1A1GFERDRD2TDP1STK17B
SCHEMBL27750596 0.79 SMN1; SMN2 (0.52) ALDH1A1GFERDRD2TDP1STK17B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250127792-A1 IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2025-04-24 US disclosed
CN-112165944-B Imidazopiperazine inhibitors of transcriptional activator proteins 德州大学系统董事会 2024-04-09 CN disclosed
US-20230008047-A1 IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2023-01-12 US disclosed
US-11058688-B2 Imidazopiperazine inhibitors of transcription activating proteins BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2021-07-13 US disclosed
CN-112165944-A Imidazopiperazine inhibitors of transcriptional activator proteins 德州大学系统董事会 2021-01-01 CN disclosed
WO-2019191667-A1 IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2019-10-03 WO disclosed
US-20190298729-A1 IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2019-10-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11058688-B2 Imidazopiperazine inhibitors of transcription activating proteins EP300, CREBBP, RBBP7 FLT1 4540/4885KDR 4089/4885ALDH1A1 3232/4885
US-20230008047-A1 IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS EP300, CREBBP, RBBP7 FLT1 4540/4885KDR 4089/4885ALDH1A1 3232/4885
US-20250127792-A1 IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS EP300, CREBBP, RBBP7 FLT1 4540/4885KDR 4089/4885ALDH1A1 3232/4885
US-20190298729-A1 IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS EP300, CREBBP, RBBP7 FLT1 4540/4885KDR 4089/4885ALDH1A1 3232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.